Source-grounded facts extracted from DAVITA INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DAVITA INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows: For Against Abstain Broker Non-Vote 51,716,491 776,849 58,589 7,313,973”
DAVITA INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows: For Against Abstain 58,286,637 1,534,241 45,024”
DAVITA INC. shareholders approved Election of the nine director nominees named below to the Company's Board of Directors for a term expiring at the 2027 Annual Meeting at the 2026-06-04 meeting.
“The Company’s stockholders elected the nine director nominees named below to the Company’s Board of Directors for a term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified. The voting results are as follows: For Against Abstain Broker Non-Vote Pamela M. Arway 51,833,209 700,475 18,245 7,313,973 Barbara J. Desoer 52,223,785 311,047 17,097 7,313,973 Jason M. Hollar 52,234,585 299,851 17,493 7,313,973 Gregory J. Moore, MD, PhD 52,463,031 71,921 16,977 7,313,973 Dennis W. Pullin 52,460,686 54,311 36,932 7,313,973 Javier J. Rodriguez 52,490,301 43,860 17,768 7,313,973 Adam H. Schechter 52,355,165 179,111 17,653 7,313,973 Wendy L. Schoppert 52,449,019 86,452 16,458 7,313,973 Phyllis R. Yale 52,227,836 306,964 17,129 7,313,973”
DAVITA INC. incurred term loan of $500 million with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender at either the Base Rate plus the Applicable Margin or Term SOFR plus the Applicable maturing May 2031.
“The Ninth Amendment, among other things, provides for an incremental borrowing under the Company's existing senior secured term loan "B" facility maturing in May 2031 (the "Tranche B-2 Term Facility" and the loans borrowed thereunder, the "Tranche B-2 Term Loans") in an aggregate principal amount of $500 million (the "Incremental Tranche B-2 Term Loans").”
DAVITA INC. amended Ninth Amendment with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender valued at $500 million (effective 2026-06-08).
“The Ninth Amendment, among other things, provides for an incremental borrowing under the Company’s existing senior secured term loan “B” facility maturing in May 2031 (the “Tranche B-2 Term Facility” and the loans borrowed thereunder, the “Tranche B-2 Term Loans”) in an aggregate principal amount of $500 million”
DAVITA INC. reported the quarter ended March 31, 2026 results: revenue $3.416 billion, net income $198 million, EPS $2.87.
“strong financial performance, and this quarter is no exception.” Financial and operating highlights for the quarter and year ended March 31, 2026: • Consolidated revenues were $3.416 billion. • Operating income was $482 million. • Diluted earnings per share from continuing operations was $2.87. • Operating cash flow was $321 million and free cash flow was $140”
DAVITA INC. amended Eighth Amendment with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender (effective 2025-11-24).
“On November 24, 2025, DaVita Inc. (the “Company”) entered into an Eighth Amendment (the “Eighth Amendment”) to that certain Credit Agreement dated as of August 12, 2019”
DAVITA INC. amended credit facility with Wells Fargo Bank, National Association at Applicable Margin for the Tranche B-2 Term Facility is 175 basis points in the c.
“a repricing of the Company’s existing senior secured term loan “B” facility maturing in May 2031”
DAVITA INC. incurred term loan of $250 million with Wells Fargo Bank, National Association at Term SOFR plus 175 basis points maturing May 2031.
“incremental borrowing of Tranche B-2 Term Loans in an aggregate principal amount of $250 million”
DAVITA INC. incurred senior notes of $1.0 billion with Wilmington Trust, National Association at 6.750% per annum maturing July 15, 2033.
“On May 23, 2025 (the “Closing Date”), DaVita Inc. (the “Company”) completed the previously announced private offering (the “Notes Offering”) of $1.0 billion aggregate principal amount of its 6.750% Senior Notes due 2033 (the “2033 Notes”).”
Michael D. Staffieri changed role as Chief Operating Officer Emeritus at DAVITA INC..
“Mr. Maughan will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of the Effective Date.”
David P. Maughan was appointed as Chief Operating Officer, DaVita Kidney Care at DAVITA INC..
“David P. Maughan, Senior Vice President of the Company, has been appointed Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024”
DAVITA INC. amended term loan of $1,640,250,847.08 with Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender at Term SOFR plus 200 basis points or Base Rate plus 100 basis points maturing May 2031.
“The Fourth Amendment, among other things, provides for an extension of the maturity date of a portion of the Company’s existing secured term loan B facility (the “Existing Tranche B-1 Term Facility”), from August 2026 to May 2031, in an aggregate principal amount of $1,640,250,847.08 (such extended portion, the “Extended Tranche B-1 Term Facility”).”
DAVITA INC. amended Fourth Amendment with Wells Fargo Bank, National Association valued at $1,640,250,847.08 (effective 2024-05-09).
“On May 9, 2024, DaVita Inc. (the “Company”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain Credit Agreement dated as of August 12, 2019”
DAVITA INC. reported for the quarter ended March 31, 2024 results: revenue $3.071 billion, net income $240, EPS $2.65.
“deliver clinical excellence,” said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: • Consolidated revenues were $3.071 billion. • Operating income was $484 million and adjusted operating income was $463 million. • Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38. •”
DAVITA INC. entered into Share Repurchase Agreement with Berkshire Hathaway Inc. valued at share repurchase agreement: Company to repurchase from Investor shares sufficient to return benefici (effective 2024-04-30).
“On April 30, 2024, DaVita Inc. (the “Company”) entered into a letter agreement (the “Share Repurchase Agreement”) with Berkshire Hathaway Inc., on behalf of itself and its Affiliates (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended) (collectively, “Investor”), the largest stockholder of the Company.”
Dennis W. Pullin was appointed as Director at DAVITA INC..
“appointing Dennis W. Pullin as a member of the Board, in each case effective as of April 10, 2024.”
DAVITA INC. reported financial results for the quarter and year ended December 31, 2023.
“On February 13, 2024, DaVita Inc. (the "Company") issued a press release announcing its financial results for the quarter ended December 31, 2023.”
DAVITA INC. reported the quarter ended September 30, 2023 results: revenue $3.1 billion, net income $247 million, EPS $2.62.
“and delivering the highest standard of care for our patients." Financial and operating highlights for the quarter ended September 30, 2023: • Consolidated revenues were $3.1 billion. • Operating income was $496 million and adjusted operating income was $525 million. • Diluted earnings per share was $2.62 and adjusted diluted earnings per share was $2.85. •”
DAVITA INC. reported the quarter ended June 30, 2023 results: revenue $3.0 billion, net income $179 million, EPS $1.91.
“to deliver strong clinical outcomes and financial results for the year." Financial and operating highlights for the quarter ended June 30, 2023: • Consolidated revenues were $3.0 billion. • Operating income was $405 million and adjusted operating income was $432 million. • Diluted earnings per share was $1.91 and adjusted diluted earnings per share was $2.08. •”
John D. Winstel departed as Chief Accounting Officer at DAVITA INC..
“when Mr. Winstel steps down from the role, no later than September 5, 2023.”
Wendy L. Schoppert was appointed as Director at DAVITA INC..
“On July 12, 2023, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from nine to ten members and appointing Wendy L. Schoppert as a member of the Board, in each case effective as of July 14, 2023.”
DAVITA INC.: Amended and restated certificate of incorporation to provide for exculpation of certain officers from liability as permitted by Delaware law (effective 2023-06-06).
“On June 6, 2023, DaVita Inc. (the “Company”) held its virtual 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved the amendment and restatement of the Company’s Restated Certificate of Incorporation to provide for the exculpation of certain officers of the Company from liability as permitted by Delaware law (the “Amendment”)”
DAVITA INC. shareholders approved Amendment and Restatement of the Company’s Restated Certificate of Incorporation to provide for the exculpation of officers as permitted under Delaware law..
“Proposal 5. Amendment and Restatement of the Company’s Restated Certificate of Incorporation to provide for the exculpation of officers as permitted under Delaware law. The Company’s stockholders approved the Amendment of the Company’s Restated Certificate of Incorporation to provide for the exculpation of certain officers of the Company from liability as permitted by Delaware law. The voting results are as follows: For Against Abstain Broker non-votes 69,041,684 4,703,320 60,494 7,030,072”
DAVITA INC. shareholders approved Advisory vote to approve the frequency of future advisory votes on named executive officer compensation..
“Proposal 4. Advisory vote to approve the frequency of future advisory votes on named executive officer compensation. The Company’s stockholders approved, on an advisory basis, holding future advisory say-on-pay votes on an annual basis. The voting results are as follows: One Year Two Years Three Years Abstain 72,480,479 20,702 1,248,836 55,481”
DAVITA INC. shareholders approved Advisory vote to approve named executive officer compensation..
“Proposal 3. Advisory vote to approve named executive officer compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows: For Against Abstain Broker non-votes 70,087,651 3,646,453 71,394 7,030,072”
DAVITA INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm. at the 2023-12-31 meeting.
“Proposal 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm. The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results are as follows: For Against Abstain 78,179,976 2,609,300 46,294”
DAVITA INC. shareholders approved Election of Directors.
“Proposal 1. Election of Directors. The Company’s stockholders elected the nine director nominees named below to the Company’s Board of Directors (“Board”) for a term expiring at the 2024 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified. The voting results are as follows: Name of Nominee For Against Abstain Broker non-votes Pamela M. Arway 69,931,446 3,844,340 29,712 7,030,072 Charles G. Berg 73,049,317 723,565 32,616 7,030,072 Barbara J. Desoer 72,535,958 1,239,118 30,422 7,030,072 Jason M. Hollar 73,225,701 549,096 30,701 7,030,072 Gregory J. Moore, MD, PhD 73,016,596 758,428 30,474 7,030,072 John M. Nehra 70,143,985 3,629,997 31,516 7,030,072 Javier J. Rodriguez 73,483,804 290,514 31,180 7,030,072 Adam H. Schechter 73,667,968 106,048 31,482 7,030,072 Phyllis R. Yale 72,679,791 1,095,878 29,829 7,030,072”
DAVITA INC. reported quarter ended March 31, 2023 results: revenue 2.873 billion, net income 116, EPS 1.25.
“trends would put us on a path to deliver strong results for the full year.” Financial and operating highlights for the quarter ended March 31, 2023: • Consolidated revenues were $2.873 billion. • Operating income was $312 million and adjusted operating income was $352 million. • Diluted earnings per share from continuing operations was $1.25 and adjusted diluted”
DAVITA INC. incurred revolving credit of up to $1.5 billion with Wells Fargo Bank, National Association at Term SOFR, plus the Applicable Margin and plus the Term SOFR Adjustment maturing five years from the closing date.
“The Third Amendment provides for (i) a new five-year secured term loan A facility in an aggregate principal amount of up to $1.25 billion (the "New A-1 Term Facility") to refinance amounts outstanding under the Company's prior $1.75 billion secured term loan A facility maturing in August 2024 (the "Prior Term A Facility") and (ii) a new five-year secured revolving credit facility in an aggregate principal amount of up to $1.5 billion (the "New Revolving Facility" and, together with the New A-1 Term Facility, the "New Facilities") to refinance amounts outstanding under the Company's prior $1.0 billion secured revolving credit facility maturing in August 2024 (the "Prior Revolving Facility").”
DAVITA INC. incurred term loan of up to $1.25 billion with Wells Fargo Bank, National Association at Term SOFR, plus the Applicable Margin and plus the Term SOFR Adjustment maturing five years from the closing date.
“The Third Amendment provides for (i) a new five-year secured term loan A facility in an aggregate principal amount of up to $1.25 billion (the "New A-1 Term Facility") to refinance amounts outstanding under the Company's prior $1.75 billion secured term loan A facility maturing in August 2024 (the "Prior Term A Facility") and (ii) a new five-year secured revolving credit facility in an aggregate principal amount of up to $1.5 billion (the "New Revolving Facility" and, together with the New A-1 Term Facility, the "New Facilities") to refinance amounts outstanding under the Company's prior $1.0 billion secured revolving credit facility maturing in August 2024 (the "Prior Revolving Facility").”
DAVITA INC. entered into Third Amendment with Wells Fargo Bank, National Association valued at up to $1.25 billion (effective 2023-04-28).
“On April 28, 2023, DaVita Inc. (the “Company”) entered into a Third Amendment (the “Third Amendment”) to that certain Credit Agreement dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified prior to the date of the Third Amendment, the “Credit Agreement”), in each case, by and among the Company, its subsidiary guarantors, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (“Wells Fargo”).”
John Winstel departed as Chief Accounting Officer at DAVITA INC..
“On March 15, 2023, John Winstel, Chief Accounting Officer of DaVita Inc. (the “Company”) notified the Company of his decision to step down from his position, with an expected transition period to end no later than September 5, 2023 (the “Effective Date”).”
DAVITA INC. reported Q4 2022 results: revenue $2.917 billion, net income $55 million, EPS $0.59.
“Financial and operating highlights for the quarter and year ended December 31, 2022: • Consolidated revenues were $2.917 billion and $11.610 billion for the three months and year ended December 31, 2022, respectively. • Operating income was $256 million and adjusted operating income was $317 million for the three months ended December 31, 2022. Operating income was $1,339 million and adjusted operating income was $1,450 million for year ended December 31, 2022. • Diluted earnings per share from continuing operations was $0.59 and adjusted diluted earnings per share from continuing operations $1.11 for three months ended December 31, 2022. Diluted earnings per share from continuing operations was $5.71 and adjusted diluted earnings per share from continuing operations was $6.60 for year ended December 31, 2022. • Operating cash flow was $344 million and free cash flow was $75 million for three months ended December 31, 2022. Operating cash flow was $1,565 million and free cash flow was”
DAVITA INC. reported financial results for the quarter ended September 30, 2022.
“On October 28, 2022, DaVita Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Adam H. Schechter was appointed as Director at DAVITA INC..
“appointed Adam H. Schechter as a member of the Board, in each case effective as of September 20, 2022.”
Jason M. Hollar was appointed as Member of the Board at DAVITA INC..
“appointed Jason M. Hollar as a member of the Board, in each case effective as of May 6, 2022.”
Gregory J. Moore was appointed as Director at DAVITA INC..
“appointed Gregory J. Moore, M.D., Ph.D. as a member of the Board, to fill the newly created vacancy on the Board, in each case effective as of September 9, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.